| HOME | ABOUT US | THE PRODUCT | BIBLIOGRAPHY | BOARD OF DIRECTORS | FAQ's | CONTACT |
 |
About
Dextro-Sang
Dextro-Sang Corporation, a privately owned biopharmaceutical company based in Toronto, Ontario, Canada, is developing Dextran-Hemoglobin, a transfusable blood substitute that can be used to assist patients suffering blood loss. Laboratory testing has shown good results in delivering oxygen in animals and the product is currently undergoing formal pre-clinical testing in Thailand with human clinical trials scheduled to begin soon. The company is optimistic that Dextran-Hemoglobin will succeed where other similar approaches have failed since it is a combination of two proven-safe substances – Dextran, a recognized plasma expander with five decades of use in emergency situations, and disease- and virus-free human hemoglobin. In December 2007 US Patents were granted. Also in March 2008 European Patents were granted. |
 |
|
 |
 |
 was developed at the University of Toronto by Dr. Jan Blumenstein and Dr. Jeffrey Wong. Since its initial development, several studies have been conducted to confirm safety and optimize its oxygen delivering capabilities. In 1998, the developers founded Dextro-Sang Corporation as a vehicle to undertake the commercialization process of Dextran-Hemoglobin.  |
Notice: The Company information is updated periodically but may not be current at time of visitation. Such information may also contain forward looking statements that are subject to risks and uncertainties that could cause actual results to differ materially, including uncertainties associated with the conduct of clinical trials. It should be noted that Dextro-Sangs's product are currently under development and that regulatory approval for the sale of its product has not been sought or attained. DEXTRO-SANG™ hemoglobin raffimer and the Logo design are trademarks of Dextro-Sang
|